Supplementary Material for Mineralocorticoid Receptor Antagonists in Dialysis Trials

A 30.2 KB DOCX file provides supplementary material for a review summarizing clinical trial evidence for mineralocorticoid receptor antagonists in dialysis patients. The review covers biological rationale, pharmacokinetic studies, and results from trials like ALCHEMIST (n=644) and ACHIEVE (n=2,538). The material was authored by figshare admin karger and last updated on 2026-04-15.

Use Cases

• Summarizing clinical trial evidence based on the review of Phase 2 and 3 trials mentioned in the description.
• Analyzing pharmacokinetic properties based on the description of spironolactone and eplerenone metabolism.
• Evaluating cardiovascular outcomes based on hazard ratios and confidence intervals from the ALCHEMIST and ACHIEVE trials.
• Assessing adverse event risks based on reported rates of hyperkalemia and gynecomastia.

Strengths

• Focuses on a specific clinical question with references to two large multicenter trials (ALCHEMIST n=644, ACHIEVE n=2,538).
• Includes specific hazard ratios and confidence intervals (e.g., HR 1.00, 95% CI 0.73–1.36) for outcome analysis.
• Released under a permissive CC-BY-4.0 license for reuse.

Limitations

• The 30.2 KB size suggests limited scope, likely a review document rather than a primary dataset.
• Row count and column-level documentation are absent; field semantics must be inferred after download.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

figshare admin karger

Collection Method

Likely a compiled review article or supplementary material.

Freshness

Last updated 2026-04-15 05:55:09; freshness should be verified.